{"hq_id":"hq-p-bdy-000129","name":"Ibuprofen and NSAIDs (GI Bleeding, Cardiovascular Risk)","category":{"primary":"personal_care","secondary":"medication","tags":["ibuprofen","NSAID","Advil","Motrin","GI bleeding","cardiovascular","kidney"]},"product_tier":"BDY","overall_risk_level":"moderate","description":"Ibuprofen (Advil, Motrin) and other NSAIDs (naproxen/Aleve, aspirin): OTC perception of safety belies significant risks with chronic use. GI bleeding: 100,000 hospitalizations/year, 16,500 deaths/year from NSAID GI complications in the US. FDA 2015 black box warning: increased cardiovascular risk (heart attack, stroke) with chronic use. Renal impairment with prolonged use. OTC dosing for short-term use is safe; the concern is chronic daily use without medical supervision.","synthesis":{"derived_risk_level":"moderate_to_high","synthesis_confidence":0.88,"synthesis_method":"compound_composition","context_used":"human_child","context_source":"product_users","exposure_modifier":0.977,"vulnerability_escalated":true,"escalation_reason":"Child exposure group","compounds_resolved":1,"compounds_total":1,"synthesis_date":"2026-03-27","synthesis_version":"1.0.0"},"hazard_summary":{"sensitive_populations":"chronic users, elderly (GI and renal), cardiovascular disease patients","overall_risk":"moderate","primary_concerns":["GI bleeding: 100,000 hospitalizations, 16,500 deaths/year from NSAIDs","FDA black box: increased cardiovascular risk (heart attack, stroke)","Renal impairment with prolonged use","OTC perception of safety encourages chronic unmonitored use"],"exposure_routes":"Oral ingestion"},"exposure":{"routes":["oral"],"contact_types":["oral_direct"],"users":["adult","child"],"duration":"minutes","frequency":"daily","scenarios":["Chronic daily NSAID use without medical supervision","GI bleeding: 100K hospitalizations, 16.5K deaths/year (US)","Cardiovascular: FDA black box warning — heart attack, stroke risk","Renal impairment from prolonged use, especially with dehydration"],"notes":"FDA 2015: strengthened cardiovascular warning on all NSAIDs (except aspirin). Risk increases with duration and dose. Short-term OTC use (≤10 days) at recommended doses is safe for most adults. NOT safe for: last trimester pregnancy (premature ductus closure), severe kidney disease, active GI bleed."},"consumer_guidance":{"usage_warning":"Limit OTC NSAID use to ≤10 days without medical guidance. Take with food. Lowest effective dose for shortest duration. Do NOT combine multiple NSAIDs. Avoid in last trimester pregnancy. Chronic use requires GI and cardiovascular risk discussion with physician.","safer_alternatives":["Acetaminophen for pain without inflammation (different mechanism)","Topical NSAIDs (Voltaren gel — reduced systemic exposure)","Non-pharmacological: ice, heat, physical therapy, TENS"],"red_flags":[{"indicator":"Health claims without FDA approval or clinical evidence","meaning":"Product efficacy unverified.","action":"Consult physician. Check FDA and clinical trial evidence."}],"green_flags":[{"indicator":"FDA-approved, USP-verified, or physician-recommended","meaning":"Verified safety and/or efficacy through established evaluation.","verification":"Check FDA approval status, USP mark, or published clinical evidence."}],"what_to_ask":[{"question":"Is there FDA-approved or peer-reviewed clinical evidence for this product?","why_it_matters":"Health products without evidence may be ineffective or harmful.","good_answer":"FDA-approved or supported by published RCTs.","bad_answer":"Testimonials only or DSHEA-exempt supplement with no clinical evidence."}],"alternatives":[{"name":"Acetaminophen for pain without inflammation","notes":"different mechanism"},{"name":"Topical NSAIDs","notes":"Voltaren gel — reduced systemic exposure"},{"name":"Non-pharmacological: ice, heat, physical therapy, TENS","notes":"Alternative"}]},"regulatory":{"applicable_regulations":[{"jurisdiction":"USA","regulation":"FDA OTC NSAID labeling","citation":"21 CFR 201","requirements":"Black box cardiovascular warning (2015). GI bleeding warning. Max 10-day OTC use without physician.","compliance_status":null,"effective_date":"2015-07-09","enforcing_agency":"FDA","penalties":null,"source_ref":null}],"certifications":[],"labeling":{"required_disclosures":[],"prop65_warning":{"required":null,"chemicals":[],"endpoint":null,"notes":null},"ghs_labeling":{"required":null,"signal_word":null,"pictograms":[],"hazard_statements":[],"notes":null},"hidden_ingredients":{"trade_secret_protected":null,"categories_hidden":[],"estimated_count":null,"known_concerns":null,"notes":null},"notes":null},"recalls":[],"regulatory_gap":null,"notes":null},"lifecycle":{"recyclable":true,"disposal_guidance":"DEA take-back or regular waste.","hazardous_waste":false,"expected_lifespan":"2-3_years"},"formulation":{"form":"varies","key_ingredients":[{"hq_id":"hq-c-org-000027","name":"Ibuprofen","role":"active_ingredient","concentration_pct":"200-800 mg/dose"}],"certifications":[]},"materials":{"common":[],"concerning":[],"preferred":[]},"compound_composition":[{"hq_id":"hq-c-org-000027","compound_name":null,"role":"active_ingredient","typical_concentration":"200-800 mg/dose"}],"identifiers":{"common_names":["ibuprofen and nsaids (gi bleeding, cardiovascular risk)"],"aliases":[],"manufacturer":null,"brands":[]},"brand_examples":[{"brand":"Johnson & Johnson","manufacturer":"J&J","market_position":"mass_market","notable":"Broad personal care portfolio"},{"brand":"Unilever","manufacturer":"Unilever","market_position":"mass_market","notable":"Global personal care conglomerate"},{"brand":"Procter & Gamble","manufacturer":"P&G","market_position":"mass_market","notable":"Personal care market leader"}],"sources":[{"type":"expert_curation","name":"ALETHEIA Safety Database","date":"2026-03-25"},{"type":"regulation","title":"FDA OTC NSAID labeling (21 CFR 201)","jurisdiction":"USA","year":2015,"citation":"21 CFR 201","id":"src_01f4ee5f"},{"id":"aspca_ibuprofen","type":"report","title":"ASPCA Animal Poison Control Center: Ibuprofen Toxicity in Pets","year":2021,"inherited_from_compound":"hq-c-org-000027"},{"id":"gwaltney_brant_2002","type":"journal","title":"Gwaltney-Brant SM: Nonsteroidal anti-inflammatory drug toxicosis. Vet Clin North Am Small Anim Pract 32(2):373–391","year":2002,"inherited_from_compound":"hq-c-org-000027"},{"type":"regulatory","title":"US Food and Drug Administration (FDA)","jurisdiction":"USA","id":"src_82d1cfcd","extraction":"description_reference"}],"meta":{"schema_version":"4.0.0","last_updated":"2026-03-25","timestamp":"2026-05-02T18:17:03.200Z"}}